Title
The role of TGF-β superfamily signaling in neurological disorders.

Permalink
https://escholarship.org/uc/item/8vr8v63k

Journal
Acta biochimica et biophysica Sinica, 50(1)

ISSN
1672-9145

Authors
Kashima, Risa
Hata, Akiko

Publication Date
2018

DOI
10.1093/abbs/gmx124

Peer reviewed
The role of TGF-β superfamily signaling in neurological disorders

Risa Kashima and Akiko Hata

1Cardiovascular Research Institute, University of California, San Francisco, CA 94143, USA, and 2Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143, USA

*Correspondence address. Tel: +1-415-476-9758; Fax: +1-415-514-1173; E-mail: akiko.hata@ucsf.edu

Received 12 September 2017; Editorial Decision 1 November 2017

Abstract

The TGF-β superfamily signaling is involved in a variety of biological processes during embryogenesis and in adult tissue homeostasis. Faulty regulation of the signaling pathway that transduces the TGF-β superfamily signals accordingly leads to a number of ailments, such as cancer and cardiovascular, metabolic, urinary, intestinal, skeletal, and immune diseases. In recent years, a number of studies have elucidated the essential roles of TGF-βs and BMPs during neuronal development in the maintenance of appropriate innervation and neuronal activity. The new advancement implicates significant roles of the aberrant TGF-β superfamily signaling in the pathogenesis of neurological disorders. In this review, we compile a number of reports implicating the deregulation of TGF-β/BMP signaling pathways in the pathogenesis of cognitive and neurodegenerative disorders in animal models and patients. We apologize in advance that the review falls short of providing details of the role of TGF-β/BMP signaling or mechanisms underlying the pathogenesis of neurological disorders. The goal of this article is to reveal a gap in our knowledge regarding the association between TGF-β/BMP signaling pathways and neuronal tissue homeostasis and development and facilitate the research with a potential to develop new therapies for neurological ailments by modulating the pathways.

Key words: cognitive disease, neurodegenerative disease, TGF-β, BMP, GDFs, neurons

Introduction

The transforming growth factor-β (TGF-β) superfamily of growth factors comprises approximately 20 evolutionarily conserved cytokines subdivided into several families, including TGF-βs, bone morphogenetic proteins (BMPs), activins, inhibins, nodals, and growth and differentiation factors (GDFs) (Table 1) [1]. They bind to two sets of ligand-specific receptors (Types I and II), which contain serine/threonine kinases. Receptor activation is transduced to the nucleus by Smad proteins, and this short cascade is known as the canonical pathway (Fig. 1) [2,3]. Smads 1, 5, and 8 are substrates of the Type I BMP receptor kinases, while Smads 2 and 3 respond to the Type I TGF-β receptor; together they are known as ‘receptor-specific’ R-Smads (Table 1). Type II receptors phosphorylate the Type I receptors, which then phosphorylate the R-Smads (Fig. 1).

The activated R-Smads bind Smad4 (Co-Smad), and then the complex translocates to the nucleus and activates (or inhibits) transcription by binding to DNA-binding transcription factors (Fig. 1). The Smad-dependent signal can be negatively regulated by inhibitory Smads (I-Smads), Smad6 and Smad7 (Table 1 and Fig. 1). It is also known that the TGF-β/BMP signal can be transduced through a variety of intracellular Smad-independent pathways, including LIM domain kinase 1 (LIMK1)-actin depolymerizing factor (ADF)-cofilin and mitogen activated protein kinase pathways (known as ‘non-canonical’) [4] (Fig. 1). In this review article, we try to discuss the roles of TGF-β signaling pathways in neuronal diseases and to reveal a gap in our knowledge regarding the association between TGF-β/BMP signaling pathways and neuronal tissue homeostasis and development.
Links between TGF-β signaling and neuronal diseases

Table 1. Molecules in the BMP, TGF-β, and activin signaling pathway in mammals and Drosophila

| Ligands | Mammals | Drosophila |
|---------|---------|------------|
| BMP     | BMP2, BMP4, GDF5, GDF6, GDF7, BMP5, BMP6, BMP7, BMP8, GDF1, GDF2, GDF3, BMP9, BMP10, BMP3, GDF10 | Dpp, Gbb, Scw |
| TGF-β   | TGF-β1, TGF-β2, TGF-β3, Lefty1, Lefty2 | Mav |
| Activin | ActivinA, ActivinB, ActivinC, ActivinE, InhivinA, InhivinC, InhivinE | Act-β, Daw |
| Type I receptors | BMP | ACVRL1 (ALK1), ACVR1 (ALK2), BMPR1A (ALK3), BMPR1B (ALK6) | Sax, Tkv |
|         | TGF-β | TβRI (ALK5), ACVRL1 (ALK1) | BaboA, BaboB, BaboC |
|         | Activin | ACVRL1 (ALK4), ACVR1C (ALK7) | BaboA, BaboB, BaboC |
| Type II receptors | BMP | BMPR2 | Wit |
|         | TGF-β | ACVRIIA (ACTRIIA), ACVRIIB (ACTRIIB) | Punt |
|         | Activin | ACVRIIA (ACTRIIA), ACVRIIB (ACTRIIB) | Punt |
| R-Smads | BMP | Smad1, Smad5, Smad8 | Mad |
|         | TGF-β | Smad2, Smad3 | Smox |
|         | Activin | Smad2, Smad3 | Smox |
| Co-Smads | BMP | Smad4 | Medea |
|         | TGF-β | Smad4 | Medea |
|         | Activin | Smad4 | Medea |
| I-Smads | BMP | Smad6, Smad7 | Dad |
|         | TGF-β | Smad7 | Dad |
|         | Activin | Smad7 | Dad |

TGF-β Superfamily in Neuronal Development and Function

The BMP signaling pathway instructs key developmental events during early development of the nervous system and cell fate specification [5,6] (Fig. 2). The activities of BMPs and downstream effectors are dynamically and carefully regulated to play key roles during gastrulation and dorso-ventral patterning within the neural tube, the embryonic precursor of the brain and the spinal cord as well as the adult brain homeostasis and functions [7]. For example, an important cell type in embryos is the neural crest, which originates from the dorsal most region of the neural tube [8]. Neural crest cells give rise to several cell types in the peripheral nervous system (PNS), including glial and Schwann cells [8]. An intermediate level of BMP signaling is required for neural crest cell generation and cell fate choice [7] (Fig. 2). BMPs also control patterning of the dorsal spinal cord [6,9,10] (Fig. 2). BMPs have been reported to activate downstream signals in the canonical BMP signaling pathway, such as ligands (GDF7 and BMP7), receptors (BMPR1A/B), and signal transducers (Smad1/5/8) are essential for patterning of the ventral spinal cord, dorsal spinal cord neural axonal guidance, forebrain development, and cerebellar granule neuron development [6,9,10] (Fig. 2). In the central nervous system (CNS), BMPs, activins, TGF-βs, and GDFs contribute to the differentiation of neural stem cells and neural progenitor cells (NPCs) [5] (Fig. 2). For example, the BMP signaling promotes astrogliogenesis, and simultaneously inhibits oligodendroglial and neuronal lineages by activating downstream signals [7] (Fig. 2). Oligodendrogenesis is inhibited by BMP signaling and promoted by noggin [5] (Fig. 2). It has been shown that BMP signaling inhibits myelination through the inhibition of oligodendrogenesis [11,12] (Fig. 2). On the contrary, TGF-β and activin signaling promote both oligodendrogenesis and myelination [5,13] (Fig. 2). Thus, the TGF-β superfamily orchestrates patterning and determination of cell fate in the CNS, as well as the PNS.

The BMP signaling pathway regulates neurite outgrowth, dendritic development, and axon growth in neurons via various Smad-dependent and -independent signaling pathways, such as those involving LIMK1−cofilin, repulsive guidance molecule (RGM), and neurogenin [5,14,15] (Fig. 1). BMP signaling also facilitates axonal transport and organization of the microtubule network in neurons [16] (Fig. 2). The BMP receptors undergo endocytosis and dynemin-dependent retrograde transport along the axon [17], implying that the trafficking of BMP receptor complexes might affect the cytoskeletal dynamics and axonal development (Fig. 2). TGF-β1–3 are found to increase the number and length of neurites [18] (Fig. 2).

The TGF-β superfamily also enhances synapse formation [19]. BMP7 and activin promote synapse development in hippocampal neurons [20] (Fig. 2). In addition, BMP signaling determines synaptic size [21], while astrocyte-derived TGF-β promotes synapse...
formation (Fig. 2) [22]. The roles of the TGF-β superfamily pathways in synapse formation have been characterized in the development of neuromuscular junctions (NMJ) in *Drosophila* [23]. Glass bottom boat (Gbb), a *Drosophila* ortholog of BMP (Table 1) secreted from muscle cells, promotes pre-synaptic formation at the NMJ [23]. Gbb binds the Type II receptor wishful thinking (Wit) and the Type I receptor thickvein (Tkv) or Saxophone (Sax) (Table 1) and regulates synaptogenesis via Smad1/5/8 (Mothers against Dpp or Mad) (Table 1) and Drosophila ortholog of LIMK1 (Linik), Maverick (Mav), a *Drosophila* ortholog of TGF-β, is secreted by glia, binds to Punt, a Type II receptor (Table 1) expressed on the surface of muscle cells, and potentiates Gbb-dependant signaling, hence promoting synaptic growth at the NMJ [24]. The TGF-β signaling pathway also regulates synaptic plasticity and memory [22]. TGF-β2 enhances synaptic transmission in primary cultured hippocampus neurons [25]. Central nervous-specific knockout (KO) of TGF-β1 in mouse exhibits a reduction of dendritic spine density, impaired long-term potentiation (LTP), and facilitated long-term depression (LTD) in CA1, CA2, and CA3 synapses in the hippocampus [26]. *Bmpr1a* and *Bmpr1b* double KO mice show reduced synaptic transmission [21,27,28]. Activin increases the number of synaptic contacts and the length of dendritic spine necks [20], suggesting that activin improves synaptic plasticity and LTP by modifying synaptic morphology [29]. Based on a transgenic mouse expressing a dominant negative variant of the activin receptor Type 1B (Acvr1B) (also known as ALK4), it has been suggested that activin signals suppress inhibitory synaptic transmission [30,31]. In summary, multiple conserved members of the TGF-β superfamily of cytokines play key roles both in synaptogenesis and in plasticity of the nervous system. In the next paragraph, we list the instances in which TGF-β superfamily pathways have been linked to the pathogenesis of different neurological disorders.

**TGF-β/BMP Signaling in Developmental Disorders**

**Fragile X syndrome**

Fragile X syndrome (FXS) (OMIM No. 300624) is the most common cause of inherited intellectual disability and the genetic cause of autism spectrum disorders (ASDs). Inactivating mutation of the *fragile X mental retardation* 1 (*FMR1*) gene, whichlocates at Xq27.3, a ‘fragile site’, or the expansion of CGG repeats (more than 200 repeats) in the 5′ UTR of *FMR1* gene, whichlocates at Xq27.3, a ‘fragile site’, or the expansion of CGG repeats (more than 200 repeats) in the 5′ UTR of *FMR1* causes FXS [32]. It is estimated that 1 in 4000 men and 1 in 8000 women are affected worldwide [32,33]. It is thought that the X chromosome with the fragile X site is more often inactivated compared with the nonaffected X chromosome [33]. FXS is diagnosed within the first 3 years of life by genetic testing. The FXS patients exhibit cognitive impairment, anxiety, hyperactivity, and autistic behavior as well as characteristic physical features, such as large and prominent ears, macroorchidism, and ovarian insufficiency [32,33]. Females with FXS tend to present less affected but wider range of phenotypic characteristics than males, depending on the inactivation ratio of the fragile X site [32]. The FMR1 gene encodes fragile X mental retardation protein (FMRP), an RNA binding protein that, in a majority of cases, represses translation [34]. Several genome-wide analyses to identify FMRP target mRNAs have been performed [35,36]. Based on the identification of FMRP targets, various pharmacological or genetic strategies to reduce the expression or activity of FMRP targets and rescue the...
pathogenesis have been employed in FXS model animals [34]. However, currently there is no effective therapy for FXS. Recently, the transcript of the Type 2 BMP receptor (BMPR2) gene has been identified as a novel target of FMRP [37] (Table 2). In FXS patients- and Fmr1-KO mice-derived brains and neurons, BMPR2 protein amount is increased [37], resulting in LIMK1 activation and increased phosphorylation of coflin [37]. The BMP-LIMK1-cofilin pathway regulates dendritogenesis and axon growth in CNS neurons [14,38]. It has been also reported that overexpression of wild-type or a constitutively active mutation in LIMK1 causes increased growth cone formation, axonal outgrowth, abnormal dendritogenesis, and impaired neural migration in primary neurons and in transgenic mice expressing a constitutively active Limk1 [39,40]. Interestingly, both Fmr1-KO mice and human FXS patients exhibit an increase of the spine density and the number of immature spines [41–44]. Genetic or pharmacological inhibition of the Smad-independent BMP-BMPR2-LIMK1-cofilin pathway rescues the neuron morphological and behavioral abnormalities in Fmr1-KO mice [37,45]. Retrograde BMP signaling also plays an important role in synapse growth and stability via both Smad-dependent and -independent (LIMK1-cofilin-dependent) pathways at the Drosophila NMJ [46,47]. Like FXS patients and Fmr1-KO mice, Drosophila Fmr1 (dfmr1) mutants have an increased number of synaptic boutons and branches at the NMJ [48–50]. These morphological

---

**Figure 2. Roles of TGF-βs and BMPs in the neural development and function**

Signaling by the TGF-β family is required for proper neural development and function. Both inductive (green arrows) and inhibitory signals (red lines) of different ligands at various steps of neural differentiation are shown. CNS and PNS stand for central nervous system and peripheral nervous system, respectively.
changes of the synapses at the NMJ are accompanied by an increase in the crawling velocity of larvae [37]. Genetic or pharmacological inhibition of the Wik-Limk pathway in larvae ameliorates the neuro-morphological and locomotive abnormalities in dFmr1 mutants [37,45], suggesting that FMRP-dependent regulation of the BMPR2-LIMK1-cofilin axis is an evolutionarily conserved pathway important for synapse development, and that aberrant activation of this pathway is one of the underlying causes of the FXS pathogenesis.

### Williams syndrome

Williams syndrome (WS) (OMIM No. 194050) is a developmental disorder characterized by mental retardation or learning difficulties, cardiovascular problems, particular facial features, and a typical personality that includes overfriendliness and anxiety [113]. The prevalence is 1 in 20,000, occurring sporadically within the general population [114]. Post-mortem layer V/VI cortical neurons in WS patients’ brain and iPS- derived neurons show longer dendrites and increased number of spines and synapses [115]. WS is caused by a deletion of the chromosome 7p11.23 locus, which comprises ~25 protein coding genes, including CYLN2, ELN, GTF2I, GTF2IRD1, FZD9, and LIMK1 [116]. LIMK1 is considered as one of the critical genes in the pathogenesis of WS [51] because Limk1-KO mice exhibit abnormalities in synapse morphology and function, enhanced hippocampus LTP, increased locomotor activity, and impaired learning [117]. Furthermore, both Limk1-KO mice and humans with the WS genetic mutation present spine abnormalities and cognitive impairment [117–119]. Additionally, overexpression of a dominant negative form of Limk1 causes aberrant axonal guidance and neuronal migration in the embryonic mouse brain [40]. As described in the FXS section above, aberrant activation of the BMPR2-LIMK1 pathway is implicated in FXS, while inhibition or inactivation of LIMK1 leads to WS [37] (Table 2). It is intriguing to speculate that restoring the BMP-BMPR2-LIMK1-cofilin activity might be able to ameliorate the pathogenesis of WS.

### Angelman syndrome

Angelman syndrome (AS) (OMIM No. 105830) is a neurodevelopmental disorder resulted mainly from deficient expression or function of the maternally inherited allele of UBE3A gene on the chromosome 15q11.2–q13 locus. The incidence of AS is between 1 in 15,000–20,000 live births.
15,000 and 1 in 20,000 [120]. The clinical features of AS are microcephaly, severe intellectual deficit, speech impairment, epilepsy, electroencephalogram abnormalities, ataxic movements, tongue protrusion, paroxysms of laughter, abnormal sleep patterns, and hyperactivity [121]. UBE3A encodes an E3 ubiquitin ligase which plays an important role in the neuronal ubiquitin-proteosome pathway and synaptic development [122-125]. Several proteins have been identified as targets of UBE3A, such as ECT2, p53, p27, HR23A, Arc, and ephexin-5 [121]. AS model mice show reduced synapse formation and experience-dependent synapse remodeling [124,126]. Mice with maternal mutation in Ube3a develop defects in context-dependent learning and LTP [127]. The neurons from the Ube3a maternal-deficient mice exhibit shorter spines and reduced dendritic spine density [125]. dUbe3a-null mutants show a reduced dendritic branching and growth of the terminal dendritic processes of sensory neurons, as well as a decreased number of satellite boutons at the NMJ in Drosophila [52,128]. Along with morphological abnormalities, deficits in locomotor behavior, circadian rhythms, and long-term memory are also observed in the dUbe3a mutants [128]. Recently, Tkv, Drosophila ortholog of BMPR1A (Table 1), has been identified as a dUbe3a target [52]. The increased activation of the Smad pathway and bouton formation in Ube3a mutants are rescued by Tkv mutation, suggesting that aberrant activation of the BMP signaling pathway is responsible for the synaptic abnormalities in AS [52]. BMPR1A (ALK3) was also identified as a target of UBE3A in human [52] (Table 2). UBE3A knockdown (KD) results in increased BMPR1A protein followed by activation of the Smad pathway, indicating that the BMP-BMPR1A signaling axis is critical for the pathogenesis of AS. Moreover, a point mutation in UBE3A has also been identified in patients with autism spectrum disorders (ASD) [129,130], suggesting that the UBE3A-BMPR1A-BMP signaling pathway might be associated with the pathogenesis of a broad range of neurodevelopmental disorders, including ASD.

Mowat-Wilson syndrome
Mowat-Wilson syndrome (MWS) (OMIM No. 235730) is a mental retardation multiple congenital anomaly syndrome characterized by typical fancies, severe mental retardation, epilepsy, and variable congenital malformations, including Hirschsprung disease (HSCR), genital anomalies, congenital heart disease (CHD), and agenesia of the corpus callosum (ACC) [131]. MWS is a very rare disease first described in 1998 [132], and the prevalence is between 1 in 50,000-70,000 [133]. Heterozygous mutation in the Smad-interacting protein-1 (SIP1) also known as ZEB2 or ZFHX1B gene causes MWS [131]. SIP1 represses Smad signaling in response to activation by BMPs and leads to the induction of neural fate [134–136] (Table 2). The BMP-Smad pathway is crucial for the generation of neural crest cells [137,138], which gives rise to a variety of cell populations in the PNS and contributes to the formation of forebrain and midbrain [139]. In zebrafish, KD of two Sip1 ortholog results in a loss of vagal/postotic neural crest cell derivatives [53]. In Sip1-KO mouse embryos, deletion of neural crest cells and inhibition in the neural crest of Msh homeobox 1 (Mash1), a BMP target gene, can be observed, suggesting that functional BMP signaling is impaired in these mice [54]. Sip1 also acts as an essential modulator of CNS myelination by inducing Smad7, an antagonist of the BMP-Smad pathway, specifically in oligodendrocytes, of which it promotes the differentiation [12]. However, the molecular mechanisms by which the SIP1 mutation affects BMP signaling in MWS patients and how SIP1-BMP signaling leads to the MWS pathogenesis remain unclear.

Hereditary spastic paraplegia
Hereditary spastic paraplegia (HSP), also known as familial spastic paraplegia, is a group of neurodegenerative disorders that leads to spastic weakness of the lower extremities [140]. HSP is classified into two groups, ‘pure HSP’ and ‘complex HSP’, according to whether the HSP occurs alone or is accompanied by additional neurological syndromes, such as cognitive impairment, dementia, epilepsy, and polyneuropathy, respectively [141]. HSP is rare and its prevalence is estimated from 1.27 to 9.6 per 100,000 [140]. Mutations in more than 40 distinct loci and 21 spastic paraplegia (SPG) genes have been associated with HSP. SPG genes encode proteins that are involved in the maintenance of corticospinal tract neurons [142] including Spartin (SPG20), Atlastin-1 (SPG3A), Spastin (SPG4), and non-imprinted in Prader-Willi/Angiokeratoma corporis diffusum-like 1 (IPW) [143, known as SPG6], some of which are inhibitory to BMP signaling [55,57]. The characteristics of different classes of HSP and their associated genes, such as Troyer syndrome (SPG20), SPG3A, SPG4, and SPG6, are discussed below.

Troyer syndrome (SPG20)
Troyer syndrome (OMIM No. 275,900) is a child-onset autosomal recessive complex HSP caused by mutation in SPART, which encodes Spartin [143]. Troyer syndrome is characterized by a progressive spastic partial paralysis of the lower limbs, motor speech disorder, and pseudobulbar palsy (inability to control facial movements), distal muscular atrophy, motor and cognitive delay, short stature, and subtle skeletal abnormalities, with both developmental and degenerative features [144]. Only 21 patients in the USA [143,144], 6 in Oman [145], and 3 in the Philippines [9] have been reported. Spartin is known to have multiple functions, including cytokinesis, endosomal trafficking and degradation of the epidermal growth factor receptor (EGFR), lipid/cholesterol metabolism, and mitochondrial function [147–152]. Interestingly, Spartin inhibits the BMP signaling pathway [55,56]. Spartin-KO mice develop progressive impairments in motor function similar to Troyer syndrome [153]. The cerebral cortical neurons from Spartin-KO mice exhibit increased branching, density of dendrites, and elongated axon length in cerebral cortical neurons [153]. In the Drosophila NMJ, Spartin localizes presynaptically [56]. Spartin homozygous mutants in Drosophila show an increase of the BMP signaling, overgrowth of synapses, and progressive neurodegeneration [56]. Mutation in Wit or the BMP inhibitor Daughters against dpp (Dad) (Table 1), an ortholog of Smads, rescues the synapse number and neurodegeneration phenotype, suggesting that Spartin negatively controls BMP signaling by promoting endocytic degradation of the Wit [56]. Therefore, these observations suggest that abnormal activation of BMP signaling is linked to the pathogenesis of Troyer syndrome (Table 2).

Spastic paraplegia-3A (SPG3A)
Mutations in the Atlastin-1 (ATL1) gene are the most common cause of pure and complex HSP with early onset at around 4 years old [141]. The ATL1 is a GTPase of the dynamin superfamily implicated in facilitating membrane interactions, fission, and fusion [154,155]. The mutants exhibit reduced GTPase activity and a prominently disrupted morphology of the endoplasmic reticulum (ER) network [156]. Knockdown of ATL1 increases (while overexpression represses) BMP signaling in zebrafish [157]. ATL1 co-localizes with the Type I BMP receptor [157] and associates with...
BMPR2 [57]. HSP-related mutations in \( AT1L \) interfere with BMPR2 trafficking to the cell surface and attenuate BMP signaling [57]. On the contrary, null mutations of \( Drosophila \) \( dATL1 \) [58] and of \( AT1L \) in mammalian cells [59] show augmented BMP activities, indicating that \( AT1L \) may also modulate trafficking, and similarly inhibit BMP signaling in mammals by interfering with microtubule dynamics and axonal guidance [58,59] (Table 2).

**Spastic paraplegia-4 (SPG4)**

Mutations in the \( Spastin \) (\( SPAST \)) gene are commonly found in autosomal dominant pure and complex HSP. SPG4 patients show sensory disturbances, sphincter dysfunction, tremor, cognitive impairment, dementia, and ataxia. SPG4 is age-dependent, and the onset peak is 10 and 30 years old [141]. \( SPAST \) interacts with microtubules and promotes microtubule disassembly, which is essential for axon growth, branching, and neuronal plasticity [158]. Mutations in \( SPAST \) cause abnormal microtubule disassembly [159]. The \( dsSpastin \) mutant \( Drosophila \) shows disorganized microtubules and disrupted proximal-distal transmission gradient along axon branches, which causes increased BMP signaling at the NMJ [57,60] (Table 2).

**Spastic paraplegia-6 (SPG6)**

SPG6 is a teenage-onset form of pure HSP, with some patients with complex HSP showing memory deficit and epilepsy [141]. All \( NIPA1 \) mutations in SPG6 are missense mutations that affect trafficking of proteins and trapping in the ER [160]. Patients lacking one copy of the \( NIPA1 \) gene seldom develop clinical HSP, thus it is unlikely that \( SPG6 \) is caused by haploinsufficiency of \( NIPA1 \), but rather by a ‘toxic gain of function’. \( NIPA1 \) binds \( AT1L \) and promotes efficient cell surface trafficking of \( AT1L \) [160]. \( NIPA1 \) also directly binds BMPR2 [55]. \( NIPA1 \) mutants, which are prone to ER trapping, reduce endocytosis, lysosomal degradation, and recycling of BMPR2, and thus augment the amount of BMPR2 on the cell surface [55] (Table 2). Transgenic rats expressing a \( NIPA1 \) mutant in neurons show an increase of BMPR2 in the spinal cord [61]. Interestingly, a null mutation of \( Spichthyin \) (\( Spict \), a \( Drosophila \) ortholog of \( NIPA1 \)) causes a distal axonal abnormality with synaptic overgrowth at the NMJ, due to the attenuation of \( \alpha Ti \) endocytosis [16]. \( Spict \) preferentially localizes in early endosomes and presynaptically regulates not only synaptic bouton formation at the NMJ but also microtubule maintenance and axonal transport, by inhibiting BMP signaling [16].

Taken together, abnormal BMPR2 endocytosis and trafficking, followed by atypical activation of BMP signaling, is closely linked to the pathology of several subtypes of HSP.

**TGF-\( \beta \)/BMP Signaling in Neurodegenerative Disorders**

The TGF-\( \beta \) family plays an extensive role in the survival of neurons [161,162]. Levels of the ligands and the receptors of TGF-\( \beta \) family are regulated following neural injury and repair for proper function of CNS [163-165]. Hippocampal astrocytes from old rats secrete higher amounts of TGF-\( \beta \)-s compared with postnatal or young rats [166]. The level of BMP4 also increases in an age-dependent manner in both human and mouse hippocampus [167], suggesting that the changes of activities of the TGF-\( \beta \) family of signaling affect the homeostasis of aging brains by altering the function and the niches of neurons. Thus, it is not surprising that the TGF-\( \beta \) family is implicated in the pathogenesis of age-related diseases, such as Alzheimer’s and Parkinson’s disease, as described below.

**Alzheimer’s disease**

Alzheimer’s disease (AD) (OMIM No. 104300) is an age-related, progressive neurodegenerative disease characterized by progressive cognitive impairment and pathological abnormalities, such as loss of neurons, amyloid plaque, and hyperphosphorylated tau in intracellular neurofibrillary tangles in the brain [168]. In addition to the neurodegenerative hallmarks, synaptic plasticity and neuronal integrity are also impaired in AD brains [169]. AD affects approximately 29.8 million people and is a major health concern worldwide [170]. Although pathological mutations in the amyloid precursor protein (APP), presenilin-1, and presenilin-2 are found in familial AD, more than 95% of AD patients do not carry these gene mutations [171]. The molecular mechanisms of pathogenesis of AD remain largely unclear.

It is likely that growth factors, such as TGF-\( \beta \)-s and BMPs, are involved in the pathogenesis of AD [172] (Table 2). The phosphorylation of Smad2/3 is decreased in the AD brain, indicative of impaired TGF-\( \beta \) signaling [62]. Nuclear Smad2, Smad3, and Smad4 are also decreased in the temporal cortex of AD patients [63]. TGF-\( \beta \) receptor Type 2 (T\( \beta \)R2) expression is decreased in neurons in AD patients [64]. It has been proposed that impaired TGF-\( \beta \) signaling in neurons contributes to \( \beta \) amyloid (A\( \beta \)) accumulation, microglia activation [65], and neurodegeneration [64]. Accordingly, exogenous TGF-\( \beta \) induces activation of microglia and clearance of A\( \beta \) and protects against A\( \beta \)-induced synapse loss, neurodegeneration, and apoptosis [66–69]. However, conflicting results have been also reported. In the brain of a mouse model of familial AD, there is an increase of TGF-\( \beta \)-1 and Smad7, an antagonist of TGF-\( \beta \) signal, which are thought to mediate neural apoptosis [70] (Table 2). Additionally, TGF-\( \beta \)-1 also affects the microglia and ameliorates neuroinflammation in AD [71]. Because TGF-\( \beta \)-1 seems to act as both survival and apoptotic factor depending on the context, the exact role of TGF-\( \beta \)-1 in AD is still unclear.

The BMP signaling pathway is also involved in AD-related neurodegeneration. In the hippocampus of AD patients, BMP6, but not BMP2 or BMP7, is augmented [72]. A\( \beta \) exposure induces BMP6, which then inhibits proliferation of NPCs [72]. Increase of BMP4 is also observed in AD mouse brains [73]. These observations suggest that augmented BMP6 is involved in AD-related altered neurogenesis. BMP4 is increased and noggin, an antagonist of BMPs, is decreased in the dentate gyrus of the AD mouse model and the apo-lipoprotein E (ApoE)-KO mice [74,75]. Several observations suggest the implication of TGF-\( \beta \)/BMP signaling in the development and progression of AD. To further understand the molecular mechanism of the pathogenesis of AD and to develop therapeutics for AD, a more precise role of TGF-\( \beta \)/BMP signaling in AD brains should be clarified in the future.

**Parkinson’s disease**

Parkinson’s disease (PD) is the second most common neurodegenerative disorder after AD, affecting 6.2 million people globally [170]. The clinical symptoms of PD include tremor at rest, rigidity, Bradykinesia, postural abnormalities and a freezing phenomenon [173]. The pathological findings in PD include a loss of nigrostriatal dopaminergic (DA) neurons with a subsequent loss of the neurotransmitter dopamine in the corpus striatum, an area of the brain which is critical for the control of movement [174]. One of the
pathological hallmarks of PD is the presence of intracellular protein aggregates called Lewy bodies [174]. Approximately 5% of PD patients carry a familial form of PD and several causal genes have been identified, including leucine rich repeat kinase 2 (LRRK2), Parkinsonism associated deglycase (PARK7), PTEN-induced putative kinase 1 (PINK1), parkin RBR E3 ubiquitin protein ligase (PRKN), and synuclein alpha (SNCA), but the genetic cause of 95% of PD is unknown [175].

It has been reported that the TGF-β superfamily signaling pathway controls DA neuron development and survival [76] (Table 2). Genetic studies suggest an association of single nucleotide polymorphisms (SNPs) in the TGFβ2 gene with PD [77]. Tgfb2+/−; Tgfb3−/− and Tgfb2−/−;Tgfb3−/− mice show a significant reduction of DA neurons at E14.5 [76]. Tgfb2−/−, Tgfb3−/−, and Smad3−/− mice show postnatal or age-dependent loss of DA neurons [76]. Adult Tgfb2−/− mice show more significant loss of striatal dopamine compared with young mice [176]. These data suggest that TGF-βs play more critical role in adult brain function and homeostasis. Neuron-specific expression of a kinase-inactive mutant Tnfr2 in mice displays age-dependent neurodegeneration in the nigrostriatal system [78]. TGF-β activation by overexpressing constitutively active Tnfr1 aborts degeneration of DA neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model [78]. In the cerebrospinal fluid of PD patients, the amount of TGF-β1 and TGF-β2 is increased [79].

BMP signaling is also involved in DA neuron differentiation and protection from neurodegeneration [80–84]. Catecholaminergic neuron-specific knock-in of a dominant negative form of BMPR2 (a truncation mutant) results in a decrease of tyrosine hydroxylase (TH), which catalyzes the formation of L-dihydroxyphenylalanine (L-DOPA), the rate-limiting step in the biosynthesis of DA, and a number of neurons in substantia nigra compacta [80]. Pretreatment with BMP7 reduces neurodegeneration in 6-hydroxydopamine (6-OHDA)-induced PD [81]. BMP7 heterozygous KO (Bmp7+/−) rats exhibit an increased sensitivity of adult DA neurons to methamphetamine [84]. BMP7 induces DA neuron differentiation from mesencephalic precursor cells in vitro [82]. BMP2 induces neurite outgrowth through Smad activation via BMPR1B in SH-SY5Y cells, which are capable of differentiating to DA neurons [83].

Finally, glial-derived neurotrophic factor (GDNF) heterozygous KO (Gdnf+/−) mice show an accelerated decline of DA neurons during aging [85]. Based on these observations, GDNF was used in clinical trials for PD [86]. GDF5 and GDF15 also play important roles in DA neuron development and survival [76]. Transplantation of GDF5-expressing CHO cells into the striatum exhibits neuroprotective and neurorestorative effects on DA neurons in a 6-OHDA-induced PD rat [87]. Thus, impairment of TGF-β superfamily signaling is closely associated with the pathogenesis of PD.

Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) (OMIM No. 105400) is a progressive neurodegenerative disease which affects the upper and lower motor neurons [184]. ALS is characterized by muscle stiffness, twitching, weakness, and atrophy throughout the body [184]. ALS affects about 2 in 100,000 individuals [184]. Mutations in >25 genes, including superoxide dismutase 1 (SOD1), alsin Rho guanine nucleotide exchange factor (ALS2), fused in sarcoma (FUS), TAR DNA-binding protein 43 (TDP43, also known as TARDBP), and chromosome 9 open reading frame 72 (C9orf72), have been identified in association with ALS, but for 90%–95% of the patients with ALS, the causal genes are unknown [185]. Irregular TGF-β signaling has been implicated in ALS pathogenesis [94–97] (Table 2). TGF-β1 is elevated in astrocytes in the spinal cord of Sod1 mutant mice and sporadic ALS patients [94]. TGF-β1–3 are also augmented in the muscle of ALS patients and Sod1 mutant mice [95]. More TGF-β1 is also detected in the serum and plasma of ALS patients [96]. Nuclear phospho-Smad2/3 (P-Smad2/3), readout of the TGF-β activity, is increased in neurons and glial cells in the spinal cord of Sod1 mutant mice as well as both familial and sporadic ALS patients [97]. Administration of TGF-β inhibitor ameliorates ALS progression in Sod1 mutant mice [94]. These reports suggest that astrocyte-derived TGF-β inhibits neuroprotective responses, promote motor neuron axon degeneration, and contribute to ALS.

TDP43 is one of the ALS-related genes [186,187]. Pathological TDP43 can lead to deregulation of the TGF-β and BMP signaling pathways in ALS [98,99]. Mutant TDP43 protein found in ALS is
prone to aggregate [188]. Interestingly, in some sporadic ALS patients, wild-type TDP43 protein is also aggregated [189,190]. The intracytoplasmic inclusion bodies containing TDP43 are associated with frontotemporal dementia and cognitive impairment in ALS [191,192]. It has also been reported that Smurf2, an E3 ubiquitin ligase that promotes ubiquitin-dependent degradation of Smad2/3 proteins, and phosphorylated Smad2/3 proteins are colocalized with TDP43 and ubiquitin within neuronal intracytoplasmic inclusions in the spinal cord and medulla oblongata of sporadic ALS patients, suggesting that the TGF-β signaling pathway is decreased in neuron [98] (Table 2). In Drosophila model of ALS, BMP signaling pathway genes (Smox, SkpA, and Sax) (Table 1) are elevated in CNS of dTDP43 mutant Drosophila according to the genome-wide transcriptome analysis [99]. Aberrant expression of TDP43 in Drosophila motor neurons mediates defective endosomal trafficking of Tkv and reduced synaptic BMP signal, leading to the impaired synaptic growth at NMJ accompanied by the abnormal larval crawling [100]. These reports suggest that deregulation of TDP43 can cause the neurological impairment in ALS pathogenesis through the impairment of the TGF-β/BMP signaling.

Mutations in the Vesicle-associated membrane protein-associated protein B (VAPB) gene are found in patients with familial ALS [193]. VAPB protein is reduced in the spinal cord of sporadic ALS patients [194]. VAPB is a Type II integral membrane protein that mainly localizes at the ER and implicated in a variety of cellular processes, including ER stress response and the unfolded protein response (UPR). A Drosophila expressing the mutant form of dVAP33A, a Drosophila ortholog of VAPB, shows reduced phospho-Mad both at NMJ and in CNS, indicative of reduced BMP signaling [101]. While it is unclear how dVAP33A modulates the BMP signaling, it is proposed that VAPB mutant might be involved in the abnormal UPR [102].

It is essential to elucidate the molecular mechanisms by which the deregulation of TGF-β signaling/BMP signaling pathway promoting ALS pathogenesis in order to develop a treatment for ALS.

Multiple sclerosis

Multiple sclerosis (MS) is an autoimmune disease with demyelination in CNS neurons [195] which affects over 2.3 million people [170]. Typically, MS patients are diagnosed in young adulthood with a higher incidence in women [195]. Clinical symptoms include blurred vision, muscle weakness and spasms as well as motor problems [195]. There are two major clinical courses of MS: (i) relapsing-remitting MS and (ii) progressive MS [195]. Despite these subtypes, all patients with MS have progressive and irreversible neurological disabilities [195]. Genome-wide association studies demonstrate that SNPs in the major histocompatibility complex (MHC) class II and DR beta 1 (HLA-DRB1) are highly associated with MS [196,197], suggesting that chronic neuroinflammation and failure of the myelin-producing cells, followed by neurodegeneration, are involved in the pathogenesis of MS [198]. Myelin is critical for the propagation of nervous impulses and axonal maintenance and is synthesized as the plasma membrane of the oligodendrocytes in the CNS [199]. During neural development, myelin and oligodendrocytes are generated from oligodendrocyte progenitors under the control of various growth factors [200]. MS plaques are characterized by the presence of immune cell infiltration, demyelination, death of mature oligodendrocytes, axonal damage and neurodegeneration [195,201]. NPCs and oligodendrocyte precursor cells (OPCs) are present in the MS lesions [202–204], suggesting that the failure of maturation of NPCs and OPCs is involved in MS pathogenesis.

The BMP signaling pathway is involved in NPC differentiation into astrocytes with concurrent suppression of oligodendroglial differentiation in adult brains, thus, deregulation of BMP signaling can contribute to demyelination in MS [106] (Table 2). Both BMPs and BMP antagonist noggin are potentially involved in MS pathology through the functions in neuronal differentiation, myelination, and immune system regulation [107]. It is thought that noggin, which is in a niche of NPCs, is associated with neurogenesis [205,206]. NPCs treated with or overexpressing noggin can differentiate into astrocytes, oligodendrocytes, and mature neurons [205,206]. Noggin is highly expressed in T cells, and the amount is reduced in MS patients [108], suggesting that the reduced production of noggin by T cells might contribute to demyelination in MS. It has also been reported that BMP4 is increased in the caudal cerebellar peduncle of rats in ethidium bromide-induced demyelinated lesions [109]. BMP4 and BMP5 are expressed at the lesions in post-mortem brain tissues from MS patients, and BMP5 expression is augmented in MS patients compared to healthy controls [110] (Table 2). T cell-derived BMP2, BMP4, and BMP5 are increased in peripheral blood mononuclear cells from MS patients [111]. The BMP signaling regulates myelination and demyelination through oligodendrogenesis [111,12]. Additionally, abnormal trafficking of BMP signaling molecules may also contribute to MS pathology [112]. Recent genome-wide association studies demonstrate that SNPs at the 16p13 locus containing C-type lectin domain family 16, member A (CLEC16A) increase the risk of MS as well as other autoimmune diseases [196,197,207,208]. CLEC16A protein in the white matter and peripheral blood mononuclear cells is increased in MS patients [209]. It has been suggested that CLEC16A promotes late endosomal maturation to disrupt the HLA-II antigen presentation pathway in MS [209]. In Drosophila, a mutation in Ena, an ortholog of CLEC16A, causes abnormal synaptic growth and defective protein trafficking [112]. Ena is an endosomal membrane protein that interacts with the class C Vps-HOPS complex to promote endosomal maturation [112]. The Ena mutant fails to form mature late endosomes and lysosomes. In the Ena mutant, Tkv, phospho-Mad, and synaptic bouton number are all increased, but they can all be reversed by overexpression of human CLEC16A [112]. These results suggest that Ena and CLEC16A inhibit BMP signaling through endolysosomal trafficking and degradation of the signaling components [112]. Compared with the BMP pathway, studies linking the TGF-β pathway to MS are limited. TGF-β is augmented in peripheral blood and cerebrospinal fluid of MS patients [103]. The amount of TGF-β and the activity of the disease are linearly correlated [104,105], suggesting that the amount of circulating TGF-β can be used as a biomarker for MS. MS is yet another example of neurodegenerative disorder associated with the deregulation of both TGF-β and BMP signaling pathways.

Anxiety, Depression, and Dementia

Anxiety, depression, and dementia are common neurological disorders that are also linked to the deregulation of TGF-β signaling [2–218]. Forebrain-specific Bmprr2-KO mice exhibit reduced anxiety-related behavior [2]. Forebrain-specific actin transgenic mice also show decreased anxiety-related behavior [211]. Major depressive disorder patients show a reduction in TGF-β in the serum or a polymorphism in the TGF-β gene [212–214]. Antidepressant treatment increases TGF-β [215]. These reports suggest that TGF-β superfamily
signaling pathways modulate psychiatric disorders. Blocking BMP signaling by either transgenic or pharmacological methods significantly enhances hippocampus-dependent learning memory behaviors [216], suggesting that BMP signaling is involved in learning and memory processes. Charged multivesicular body protein 2B (CHMP2B) mutations are related with frontotemporal dementia [217]. Overexpression of Rab8, a negative regulator of TGF-β signaling, rescued synapse overgrowth phenotype in Chmp2b mutant Drosophila [218], implying that an overactive TGF-β signaling pathway is involved in frontotemporal dementia pathogenesis.

Conclusion
The TGF-β family of growth factors plays essential roles during embryonic development and in the regulation of tissue homeostasis. Here we summarized studies describing the association of deregulation of TGF-β signaling with neuronal development and neurological disorders. Abundant evidence in both invertebrates and vertebrates indicates that the TGF-β pathways play important roles in the maintenance of neuron and spine homeostasis. Causal links between deregulation of TGF-β signaling pathway and human disorders such as cancer and cardiovascular or bone diseases have been well documented, and a number of therapeutic molecules have been generated. Compared to other human diseases, the current knowledge of how TGF-β pathways lead to various neurological abnormalities is limited. Many studies are rather descriptive than mechanistic. We hope that this article will provide a basis for future research aimed at providing more mechanistic insights into neurological abnormalities stemming from deregulation of TGF-β signaling, which are essential for the future development of targeted therapies.

Acknowledgements
We thank Dr. G. Lagna (Cardiovascular Research Institute, University of California, San Francisco, USA) for critical reading of the review. We also thank all current and past members of the Hata lab for their contributions to the scientific work performed from our laboratory.

Funding
This work was supported by the grants from the NIH (Nos. HL093154 and HL108317) and the Catalyst Award from UCSF Clinical and Translational Science Institute (CTSI).

References
1. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007, 8: 970–982.
2. Heldin CH, Moustakas A. Signaling receptors for TGF-beta family members. Cold Spring Harb Perspect Biol 2016, 8: a022053.
3. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012, 13: 616–630.
4. Zhang YE. Non-Smad signaling pathways of the TGF-beta family. Cold Spring Harb Perspect Biol 2017, 9: 022095.
5. Meyers EA, Kessler JA. TGF-beta family signaling in neural and neuronal differentiation, development, and function. Cold Spring Harb Perspect Biol 2017, 9: a022244.
6. Hegarty SV, O’Keefe GW, Sullivan AM. BMP-Smad 1/5/8 signaling in the development of the nervous system. Prog Neurobiol 2013, 109: 28–41.
7. Bond AM, Rhalala OG, Kessler JA. The dynamic role of bone morphogenetic proteins in neural stem cell fate and maturation. Dev Neurobiol 2012, 72: 1068–1084.
8. Kalcheim C, Kumar D. Cell fate decisions during neural crest ontogeny. Int J Dev Biol 2017, 61: 195–203.
9. Le Dreau G, Marti E. The multiple activities of BMPs during spinal cord development. Cell Mol Life Sci 2013, 70: 4293–4305.
10. Liu A, Niswander LA. Bone morphogenetic protein signalling and vertebrate nervous system development. Nat Rev Neurosci 2005, 6: 945–954.
11. See JM, Grinspan JB. Sending mixed signals: bone morphogenetic protein in myelination and demyelination. J Neuropathol Exp Neurol 2009, 68: 595–604.
12. Weng Q, Chen Y, Wang H, Xu X, Yang B, He Q, Shou W, et al. Dual-mode modulation of Smad signaling by Smad-interacting protein Sp1 is required for myelination in the central nervous system. Neuron 2012, 73: 713–728.
13. Dutta DJ, Zameer A, Mariani JN, Zhang J, Asp J, Huynh J, Mahase S, et al. Combinatorial actions of Tgfbeta and Activin ligands promote oligodendrocyte development and CNS myelination. Development 2014, 141: 2414–2428.
14. Lee-Hoeftich ST, Causing CG, Podkowa M, Zhao X, Wrana JL, Attisano L. Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. EMBO J 2004, 23: 4792–4801.
15. Zhong J, Zou H. BMP signaling in axon regeneration. Curr Opin Neurobiol 2014, 27: 127–134.
16. Wang X, Shaw WR, Tsang HT, Reid E, O’Kane CJ. Drosophila spichthyin inhibits BMP signaling and regulates synaptic growth and axonal microtubules. Nat Neurosci 2007, 10: 177–185.
17. Smith RB, Machamer JB, Kim NC, Hays TS, Marques G. Relay of retrograde synaptogenic signals through axonal transport of BMP receptors. J Cell Sci 2012, 125: 3752–3764.
18. Unsicker K, Meier C, Kriegstein K, Sartor BM, Flanders KC. Expression, localization, and function of transforming growth factor-beta s in embryonic chick spinal cord, hindbrain, and dorsal root ganglia. J Neurobiol 1996, 29: 262–276.
19. Poon VY, Choi S, Park M. Growth factors in synaptic function. Front Synaptic Neurosci 2013, 5: 6.
20. Shoji-Kasai Y, Ageta H, Hasegawa Y, Tsuchida K, Sugino H, Inokuchi K. Activin increases the number of synaptic contacts and the length of dendritic spine necks by modulating synaptic actin dynamics. J Cell Sci 2007, 120: 3830–3837.
21. Xiao L, Michalski N, Kronander E, Gjoni E, Genoud C, Knott G, Schneggenburger R. BMP signaling specifies the development of a large and fast CNS synapse. Nat Neurosci 2013, 16: 856–866.
22. Diniz LP, Mattas IC, Garcia MN, Gomes FC. Astrocytic control of neural circuit formation: highlights on TGF-beta signaling. Neurochem Int 2014, 78: 18–27.
23. Upadhyay A, Moss-Taylor L, Kim MJ, Ghosh AC, O’Connor MB. TGF-beta family signaling in Drosophila. Cold Spring Harb Perspect Biol 2017, 9: a031963.
24. Fuentes-Medel Y, Ashley J, Barria R, Maloney R, Freeman M, Budnik V. Integration of a retrograde signal during synapse formation by glia-secreted TGF-beta ligand. Curr Biol 2012, 22: 1831–1838.
25. Fukushima T, Liu RY, Byrne JH. Transforming growth factor-beta2 modulates synaptic efficacy and plasticity and induces phosphorylation of CREB in hippocampal neurons. Hippocampus 2007, 17: 5–9.
26. Koegeloperger T, Li S, Brennan C, Saulnier JL, Mayo L, Carrier Y, Selkoe DJ, et al. Impaired glutamate recycling and GluN2B-mediated neuronal calcium overload in mice lacking TGF-beta1 in the CNS. Glia 2013, 61: 985–1002.
27. Aherle H, Haghighi AP, Fetter RD, McCabe BD, Magalhaes TR, Goodman CS. wishful thinking encodes a BMP type II receptor that regulates synaptic growth in Drosophila. Neuron 2002, 33: 545–558.
28. McCabe BD, Marques G, Haghighi AP, Fetter RD, Crotty ML, Haerry TE, Goodman CS, et al. The BMP homolog Gbb provides a retrograde
signal that regulates synaptic growth at the Drosophila neuromuscular junction. *Neuron* 2003, 39: 241–254.

29. Kriegstein K, Zheng F, Unsicker K, Alzheimer C. More than being protective: functional roles for TGF-beta/activin signaling pathways at central synapses. *Trends Neurosci* 2011, 34: 421–429.

30. Zheng F, Adelsberger H, Muller MR, Frischy JM, Werner S, Alzheimer C. Activin tunes GABAergic neurotransmission and modulates anxiety-like behavior. *Mol Psychiatry* 2009, 14: 312–346.

31. Zheng F, Puppel A, Huber SE, Link AS, Eulenburg V, van Brederode JF, Muller CP, et al. Activin controls ethanol potentiation of inhibitory synaptic transmission through GABA receptors and concomitant behavioral sedation. *Neuropsychopharmacology* 2016, 41: 2024–2033.

32. Salidarraga W, Tassone F, Gonzalez-Tushima LY, Forero-Forero JV, Ayala-Zapata S, Hagerman R. Fragile X syndrome. *Colomb Med (Cali)* 2014, 45: 190–198.

33. Santos AR, Kanellopoulos AK, Bagni C. Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us. *Learn Mem* 2014, 21: 543–555.

34. Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. *Nat Rev Neurosci* 2015, 16: 595–605.

35. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. *Cell* 2001, 107: 489–499.

36. Ascano M Jr, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. Fragile X mental retardation protein targets distinct mRNAs in the central nervous system. *Nature* 2012, 492: 382–386.

37. Kashima R, Roy S, Ascano M, Martinez-Cardenos V, Araza-Torres J, Kim S, Louie J, et al. Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome. *Sci Signal* 2016, 9: ra58.

38. Yamauchi K, Varadarajan SG, Li JE, Butler SJ. Type Ib BMP receptors mediate the rate of commissural axon extension through inhibition of BMP signaling in Drosophila melanogaster. *Dev Biol* 2004, 15: 3433–3449.

39. Xie J, Li X, Zhang W, Chai X, Huang Y, Li K, Cheng X, et al. Altered expression of LIMK1 impairs neuronal migration during neocortex development. *Histochem Cell Biol* 2017, 147: 471–479.

40. Grossman AW, Elissoueu NM, McKinney BC, Greenough WT. Hippocampal pyramidal cells in adult Fmr1 knockout mice exhibit an immature-appearing profile of dendritic spines. *Brain Res* 2006, 1084: 158–164.

41. McKinney BC, Grossman AW, Elissoueu NM, Greenough WT. Dendritic spine abnormalities in the occipital cortex of C57BL/6 Fmr1 knockout mice. *Am J Med Genet B Neuropsychiatr Genet* 2005, 136B: 98–102.

42. Irwin SA, Galvez R, Greenough WT. Dendritic spine structural abnormalities in fragile-X mental retardation syndrome. *Cereb Cortex* 2000, 10: 1038–1044.

43. Kashima R, Redmond PL, Ghatpande P, Roy S, Kornberg TB, Hanke T, Knapp S, et al. Hyperactive locomotion in a Drosophila model is a functional readout for the synaptic abnormalities underlying fragile X syndrome. *Sci Signal* 2017, 10(52): eaai8133.

44. Piccoli ZD, Lortjet JF. Retrograde BMP signaling modulates rapid activity-dependent synaptic growth via presynaptic LIM kinase regulation of cofilin. *J Neurosci* 2014, 34: 4371–4381.

45. Eaton BA, Davis GW. LIM Kinase1 controls synaptic stability downstream of the type II BMP receptor. *Neuron* 2005, 47: 695–708.

46. Zhang YQ, Bailey AM, Matteis HJ, Renden RB, Smith MA, Speese SD, Rubin GM, et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. *Cell* 2001, 107: 591–603.

47. Pan L, Zhang YQ, Woodruff E, Broadie K. The Drosophila fragile X gene negatively regulates neuronal elaboration and synaptic differentiation. *Carr Biol* 2004, 14: 1863–1870.

48. Myrick LC, Deng PY, Hashimoto H, Oh YM, Cho Y, Poidevin MJ, Suhl JA, et al. Independent role for presynaptic FMRP revealed by an FMR1 missense mutation associated with intellectual disability and seizures. *Proc Natl Acad Sci USA* 2015, 112: 949–956.

49. Hoogenraad CC, Akhanmanov A, Galjart N, De Zeeuw CJ. LIMK1 and CLIP-115: linking cytoskeletal defects to Williams syndrome. *Bioessays* 2004, 26: 141–150.

50. Li W, Yao A, Zhu H, Kaur K, Zhu YC, Jia M, Zhao H, et al. Angelman syndrome protein Ube3a regulates synaptic growth and endocytosis by inhibiting BMP signaling in Drosophila. *PLoS Genet* 2016, 12: e1006062.

51. Delandame JM, Guyote ME, Smith CM, Shepherd FT. Zebrafish sps1a and sps1b are essential for normal axial and neural patterning. *Dev Dyn* 2008, 237: 1060–1069.

52. Van de Putte T, Maruhashi M, Francis A, Nelles L, Kondoh H, Huybrechock D, Higashi Y. Mice lacking ZFHX1B, the gene that codes for Smad-interacting protein-1, reveal a role for multiple neural crest cell defects in the etiology of Hirschsprung disease-neural-territorial retardation syndrome. *Am J Hum Genet* 2003, 72: 465–470.

53. Tsang HT, Edwards TL, Wang X, Connell JW, Davies RJ, Durrington HJ, O’Kane CJ, et al. The hereditary spastic paraplegia proteins NIPA1, spastin and spartin are inhibitors of mammalian BMP signalling. *Hum Mol Genet* 2009, 18: 3805–3821.

54. Nahm M, Lee MJ, Parkinson W, Lee M, Kim H, Kim YJ, Kim S, et al. Spartin regulates synaptic growth and neuronal survival by inhibiting BMP-mediated microtubule stabilization. *Neuron* 2013, 77: 680–695.

55. Zhao J, Heder P. Hereditary spastic paraplegia-causing mutations in atlastin-1 interfere with BMPRII trafficking. *Mol Cell Neurosci* 2013, 52: 87–96.

56. Summerville JB, Faust JF, Fan E, Pendin D, Daga A, Formella J, Stern M, et al. The effects of ER morphology on synaptic structure and function in Drosophila melangaster. *J Cell Sci* 2016, 129: 1635–1648.

57. Zhao G, Zhu PP, Renvoise B, Maldonado-Baez L, Park SH, Blackstone C. Mammalian knock out cells reveal prominent roles for atlatin GTases in ER network morphology. *Exp Cell Res* 2016, 349: 52–44.

58. Ball RW, Peled ES, Guerrero G, Isacoff EY. BMP signaling and microtubule organization regulate synaptic strength. *Neuroscience* 2015, 291: 135–166.

59. Watanabe F, Arnold WD, Hammer RE, Ghodsizadeh O, Moti H, Schumer M, Hashmi A, et al. Pathogenesis of autosomal dominant hereditary spastic paraplegia (SPG6) revealed by a rat model. *J Neuropathol Exp Neurol* 2013, 72: 1016–1028.

60. Ueberham U, Ueberham E, Gruschka H, Arendt T. Altered subcellular location of phosphorylated Smads in Alzheimer’s disease. *Eur J Neurosci* 2006, 24: 2327–2334.

61. Ueberham U, Hilschirn I, Ueberham E, Rohn S, Glockner P, Dietrich K, Bruckner MK, et al. Transcriptional control of cell cycle-dependent kinase 4 by Smad proteins—implications for Alzheimer’s disease. *Neurobiol Aging* 2012, 33: 2827–2840.

62. Tesser I, Zou K, Exposito I, Bard F, Berber E, Can JV, Lin AH, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology. *J Clin Invest* 2006, 116: 3060–3069.

63. Tichauer JE, von Bernhardt R. Transforming growth factor-beta stimulates beta amyloid uptake by microglia through Smad3-dependent mechanisms. *J Neurosci Res* 2012, 90: 1970–1980.

64. WynnTAYLOR T, Lin C, Yan F, Yu GQ, Rohde M, McGonagle L, Masliah E, et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. *Nat Med* 2001, 7: 612–618.

65. Caraci F, Battaglia G, Bruno V, Bosco P, Carbonaro V, Guiffrida ML, Drago F, et al. TGF-beta1 pathway as a new target for neuroprotection in Alzheimer’s disease. *CNS Neurosci Ther* 2011, 17: 237–249.
68. Fischella V, Guadanello G, Platania CB, Romano GL, Leggio GM, Salomone S, Drago F, et al. TGF-beta1 prevents rat retinal insult induced by amyloid-beta (1-42) oligomers. Eur J Pharmacol 2016, 787: 72-77.

69. Diniz LP, Tortelli V, Maitas I, Morgado J, Bergamo Araujo AP, Melo HM, Sexas da Silva GS, et al. Astrocyte transforming growth factor beta 1 protects synapses against Abeta oligomers in Alzheimer’s disease model. J Neurosci 2017, 37: 6797–6809.

70. Salins P, He Y, Olson K, Glazner G, Kashour T, Amara F. TGF-beta1 is increased in a transgenic mouse model of familial Alzheimer’s disease and causes neuronal apoptosis. Neurosci Lett 2008, 430: 81–86.

71. Huang WC, Yen FC, Shie FS, Fan CM, Shiao YJ, Yang CN, Huang FL, et al. TGF-beta1 blockade of microglial chemotaxis toward Abeta aggregates involves SMAD signaling and down-regulation of CCL5. J Neuroinflammation 2010, 7: 28.

72. Crews L, Adame A, Patrick C, Delaney A, Pham E, Rockenstein E, Hansen L, et al. Increased BMP6 levels in the brains of Alzheimer’s disease patients and APP transgenic mice are accompanied by impaired neurogenesis. J Neurosci 2010, 30: 12252–12262.

73. Kwak YD, Hendrix BJ, Sugaya K. Secreted type of amyloid precursor protein induces glial differentiation by stimulating the BMP/Smad signaling pathway. Biochem Biophys Res Commun 2014, 447: 394–399.

74. Tang J, Song M, Wang Y, Fan X, Xu H, Bai Y. Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APP(we/ps1) (DeltaE9) transgenic mouse model of Alzheimer’s disease. Biochem Biophys Res Commun 2009, 385: 341–345.

75. Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K, Hegarty SV, Sullivan AM, O’Keeffe JW, et al. TGF-beta1 and BMP4 family in the development and survival of midbrain dopaminergic neurons. Mol Neurobiol 2014, 50: 559–573.

76. Goris A, Williams-Gray CH, Foltynie T, Brown J, Maranian M, Walton J, Liu S, et al. Transforming growth factor-beta signaling in human midbrain dopaminergic neurons. Mol Neurobiol 2014, 48: 846–848.

77. Tesser I, Nguyen A, Chang B, Li L, Woodling NS, Wysy-Coray T, Luo Y. Deficiency in neuronal TGF-beta signaling leads to nigrostriatal degeneration and activation of TGF-beta signaling protects against MPTP neurotoxicity in mice. J Neurosci 2017, 37: 4534–4592.

78. Vawter MP, Dillen-Carter O, Toutoulette WW, Carvey P, Freed WJ. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson’s disease cerebrospinal fluid. Exp Neurol 1996, 142: 313–322.

79. Chou J, Harvey BK, Etendal T, Hoffer B, Wang Y. Nigrostriatal alterations in bone morphogenetic protein receptor II dominant negative mice. Acta Neurol Scand Suppl 2008, 101: 93–98.

80. Harvey BK, Mark A, Chou J, Chen GJ, Hoffer BJ, Wang Y. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson’s disease. Brain Res 2004, 1022: 88–95.

81. Lee JY, Koh HC, Chang MY, Park CH, Lee YS, Lee SH. Erythropoietin induces glial differentiation by stimulating the BMP/Smad signaling pathway. J Neuroinflammation 2015, 12: 571.

82. Liang LP, Tortelli V, Maitas I, Morgado J, Bergamo Araujo AP, Melo HM, Sexas da Silva GS, et al. Astrocyte transforming growth factor beta 1 protects synapses against Abeta oligomers in Alzheimer’s disease model. J Neurosci 2017, 37: 6797–6809.

83. Battaglia G, Cannella M, Rizzi B, Orobello S, Matt-Schienman ML, Aronica E, Bucchi CE, et al. Early defect of transforming growth factor beta 1 formation in a model of Huntington’s disease. J Cell Mol Med 2011, 15: 555–571.

84. Liu KL, An MC, Zhang N, O’Brien RN, Ramos EM, Gao F, Arwood R, et al. Genomic analysis reveals disruption of striatal neuronal development and therapeutic targets in human Huntington’s disease neurostem cells. Stem Cell Rep 2015, 5: 1023–1038.

85. Kandasamy M, Coulard-Despres S, Raber KA, Stephan M, Lehner B, Winner B, Kohl Z, et al. Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated transforming growth factor-beta signaling in an animal model of Huntington disease. J Neurotroph Exp Neurol 2010, 69: 717–728.

86. Bowles KR, Stone T, Holman P, Allen ND, Dunnett SB, Jones L. SMAD transcription factors are altered in cell models of HD and regulate HTT signal. Cell Signaling 2017, 31: 1–14.

87. Antonov Y, Littleton JT. Pathogenic Huntington Alters BMP Signaling and synaptic growth through local disruptions of endosomal compartments. J Neurosci 2013, 37: 3423–3439.

88. Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, Sobue G, et al. Astrocyte-derived TGF-beta1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep 2015, 11: 592–604.

89. Si Y, Kim S, Cui X, Zheng L, Oh SJ, Anderson T, AliSharabati M, et al. Transforming growth factor beta (TGF-beta) Is a muscle biomarker of disease progression in ALS and correlates with Smad expression. PLoS One 2015, 10: e0138425.

90. Ilezeck J, Stelmasiak Z, Dobosz B. Transforming growth factor-beta 1 (TGF-beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 2002, 20: 239–243.

91. Nakamura M, Ito H, Wate R, Nakano S, Hirano A, Kusaka H. Phosphorylated Smad2/3 immunoreactivity in sporadic and familial amyotrophic lateral sclerosis and its mouse model. Acta Neuropathol 2008, 113: 327–334.

92. Nakamura M, Kaneko S, Wate R, Asayama S, Nakamura Y, Fujita K, Ito H, et al. Regionally different immunoreactivity for Smurfl2 and pSmad2/3 in TDP-43-positive inclusions of amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 2015, 129: 901–913.

93. Hazlelett DJ, Chang JC, Lakeland DL, Morton DB. Comparison of parallel high-throughput RNA sequencing between knockout of TDP-43 and its overexpression reveals primarily nonreciprocal and nonoverlapping gene expression changes in the central nervous system of Drosophila. G3 (Bethesda) 2012, 2: 789–802.

94. Deshpande M, Feiger Z, Shilton AK, Luo CC, Silverman E, Rodal AA. Role of BMP receptor traffic in synaptic growth defects in an ALS model. Mol Biol Cell 2016, 27: 2898–2910.

95. Ramaprakhia A, Lawless GM, Schweizer FE, Golshani P, Jackson GR. A Drosophila model of ALS: human ALS-associated mutation in VAP33A elicits of Parkinson’s disease progression and correlates with Smad expression. J Neurosci 2010, 30: 12252–12262.

96. Ramaprakhia A, Lawless GM, Schweizer FE, Golshani P, Jackson GR. A Drosophila model of ALS: human ALS-associated mutation in VAP33A elicits of Parkinson’s disease progression and correlates with Smad expression. J Neurosci 2010, 30: 12252–12262.

97. Ramaprakhia A, Lawless GM, Schweizer FE, Golshani P, Jackson GR. A Drosophila model of ALS: human ALS-associated mutation in VAP33A elicits of Parkinson’s disease progression and correlates with Smad expression. J Neurosci 2010, 30: 12252–12262.
105. Bertolotto A, Capobianco M, Malucchi S, Manzardo E, Audano L, Bergui M, Bradac GB, et al. Transforming growth factor beta1 (TGFbeta1) mRNA level correlates with magnetic resonance imaging disease activity in multiple sclerosis patients. *Neurosci Lett* 1999, 263: 21–24.

106. Grinspan JB. Bone morphogenetic proteins: inhibitors of myelination in development and disease. *Vitam Horm* 2015, 99: 195–222.

107. Eixarch H, Calvo-Barreiro I, Montalban X, Espejo C. Bone morpho-
genetic proteins in multiple sclerosis: role in neuroinflammation. *Brain Behav Immun* 2017, doi:10.1016/j.bbi.2017.02.019.

108. Urshansky N, Mausner-Fainberg K, Auriel E, Karni A. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis. *J Neuroimmunol* 2011, 232: 171–178.

109. Zhang Y, Zhang Y, Tregoubov V, Janus C, Cruz L, Jackson M, Lu WY, et al. GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. *Cell* 2010, 143: 442–455.

110. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, Sweatt JD, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. *Neuron* 1998, 21: 799–811.

111. Lu Y, Wang F, Li Y, Ferris J, Lee JA, Gao PB. The Drosophila homo-
logue of the Angelman syndrome ubiquitin ligase regulates the forma-
tion of terminal dendritic branches. *Hum Mol Genet* 2009, 18: 454–462.

112. Yi JJ, Berrios J, Newbern JN, Snider WD, Philpott BD, Hahn KM, Zylka MJ. An Autism-linked mutation disables phosphorylation control of UBE3A. *Cell* 2015, 162: 795–807.

113. Lossoflo L, O’Roak BJ, Sanderv SJ, Ronenmes M, Krumm N, Ley D, Stessman HA, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014, 515: 216–221.

114. Bertolotto A, Capobianco M, Malucchi S, Manzardo E, Audano L, Bergui M, Bradac GB, et al. Transforming growth factor beta1 (TGFbeta1) mRNA level correlates with magnetic resonance imaging disease activity in multiple sclerosis patients. *Neurosci Lett* 1999, 263: 21–24.

115. Garcia MM, Calvo-Barrero I, Montalban X, Espejo C. Bone morpho-
genetic proteins in multiple sclerosis: role in neuroinflammation. *Brain Behav Immun* 2017, doi:10.1016/j.bbi.2017.02.019.

116. Urshansky N, Mausner-Fainberg K, Auriel E, Karni A. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis. *J Neuroimmunol* 2011, 232: 171–178.

117. Zhang Y, Zhang Y, Tregoubov V, Janus C, Cruz L, Jackson M, Lu WY, et al. GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. *Cell* 2010, 143: 442–455.

118. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, Sweatt JD, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. *Neuron* 1998, 21: 799–811.

119. Lu Y, Wang F, Li Y, Ferris J, Lee JA, Gao PB. The Drosophila homo-
logue of the Angelman syndrome ubiquitin ligase regulates the forma-
tion of terminal dendritic branches. *Hum Mol Genet* 2009, 18: 454–462.

120. Yi JJ, Berrios J, Newbern JN, Snider WD, Philpott BD, Hahn KM, Zylka MJ. An Autism-linked mutation disables phosphorylation control of UBE3A. *Cell* 2015, 162: 795–807.

121. Lossoflo L, O’Roak BJ, Sanderv SJ, Ronenmes M, Krumm N, Ley D, Stessman HA, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014, 515: 216–221.

122. Lara A, Albrecht U, Atkins CM, Noebels JL, Eichele G, Sweatt JD, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. *Neuron* 1998, 21: 799–811.

123. Lossoflo L, O’Roak BJ, Sanderv SJ, Ronenmes M, Krumm N, Ley D, Stessman HA, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014, 515: 216–221.

124. Garcia MM, Calvo-Barrero I, Montalban X, Espejo C. Bone morpho-
genetic proteins in multiple sclerosis: role in neuroinflammation. *Brain Behav Immun* 2017, doi:10.1016/j.bbi.2017.02.019.

125. Urshansky N, Mausner-Fainberg K, Auriel E, Karni A. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis. *J Neuroimmunol* 2011, 232: 171–178.

126. Zhang Y, Zhang Y, Tregoubov V, Janus C, Cruz L, Jackson M, Lu WY, et al. GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. *Cell* 2010, 143: 442–455.

127. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, Sweatt JD, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. *Neuron* 1998, 21: 799–811.

128. Lu Y, Wang F, Li Y, Ferris J, Lee JA, Gao PB. The Drosophila homo-
logue of the Angelman syndrome ubiquitin ligase regulates the forma-
tion of terminal dendritic branches. *Hum Mol Genet* 2009, 18: 454–462.

129. Yi JJ, Berrios J, Newbern JN, Snider WD, Philpott BD, Hahn KM, Zylka MJ. An Autism-linked mutation disables phosphorylation control of UBE3A. *Cell* 2015, 162: 795–807.

130. Lossoflo L, O’Roak BJ, Sanderv SJ, Ronenmes M, Krumm N, Ley D, Stessman HA, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014, 515: 216–221.

131. Lara A, Albrecht U, Atkins CM, Noebels JL, Eichele G, Sweatt JD, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. *Neuron* 1998, 21: 799–811.

132. Lossoflo L, O’Roak BJ, Sanderv SJ, Ronenmes M, Krumm N, Ley D, Stessman HA, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014, 515: 216–221.

133. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

134. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

135. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

136. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

137. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

138. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

139. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

140. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

141. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

142. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

143. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

144. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.

145. Adam MP, Conta J, Bean LJH Mowat-Wilson Syndrome. 1993.
functionality observed in the aging brain. Mol Neurobiol 2017, 54:
2969–2985.

167. Meyers EA, Gobeske KT, Bond AM, Jarrett JC, Peng CY, Kessler JA.
Increased bone morphogenetic protein signaling contributes to age-
related declines in neurogenesis and cognition. Neurobiol Aging 2016,
38: 164–175.

168. Burns A, Iliffe S. Alzheimer’s disease. Br Med J 2009, 338: b158.

169. Ondrejcek T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ.
Alzheimer’s disease amyloid beta-protein and synaptic function. Neuro-
romolecular Med 2010, 12: 13–26.

170. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators.
Global, regional, and national incidence, prevalence, and years lived
with disability for 310 diseases and injuries, 1990-2015: a systematic
analysis for the Global Burden of Disease Study 2015. Lancet 2016,
388: 1545–1602.

171. Cacace R, Sleeeger K, Van Broeckhoven C. Molecular genetics of early-
onset Alzheimer’s disease revisited. Alzheimers Dement 2016, 12:
73–748.

172. Lauzon MA, Daviao A, Marcos B, Faucheux N. Growth factor treat-
ment to overcome Alzheimer’s dysfunctional signaling. Cell Signal
2015, 27: 1025–1038.

173. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease.
J Neurochem 2016, 139(Suppl 1): 318–324.

174. Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine,
vesicles and alpha-synuclein. Nat Rev Neurosci 2002, 3: 932–942.

175. Houlden H, Singleton AB. The genetics and neuropathology of Parkin-
son’s disease. Acta Neuropathol 2012, 124: 325–338.

176. Andrews ZB, Zhao H, Frugger T, Meguro R, Grattan DR, Koishi K,
McLennan BS. Transforming growth factor beta2 haploinsuffi-
cient mice develop age-related nigrostriatal dopamine deficits. Neurobiol
Dis 2006, 21: 568–575.

177. The Huntington’s Disease Collaborative Research Group. A novel gene
containing a trinucleotide repeat that is expanded and unstable on
Huntington’s disease chromosomes. Cell 1993, 72: 971–983.

178. Mendez MF. Huntington’s disease: update and review of neuropsy-
chiatric aspects. Int J Psychiatry Med 1994, 24: 189–208.

179. Pringsheim T, Wilshtire K, Day L, Dykeman J, Steeves T, Jette N. The
incidence and prevalence of Huntington’s disease: a systematic review
and meta-analysis. Mov Disord 2012, 27: 1083–1091.

180. Hoffner G, Dijan P. Polyglutamine aggregation in Huntington disease:
does structure determine toxicity? Mol Neurobiol 2015, 52: 1297–1314.

181. Jimenez-Sanchez M, Licitira F, Underwood BR, Rubinsztein DC.
Huntington’s disease: mechanisms of pathogenesis and therapeutic strat-
egies. Cold Spring Harb Perspect Med 2017, 7: a024240.

182. Takahashi T, Katada S, Onodera O. Polyglutamine diseases: where
does toxicity come from? what is toxicity? where are we going? J Mol Cell
Biol 2010, 2: 180–191.

183. Ferrante RJ, Kowall NW, Richardson EP Jr. Proliferative and degenera-
tive changes in striatal spiny neurons in Huntington’s disease: a com-
bined study using the section-Golgi method and calbindin D28k
immunocytochemistry. J Neurosci 1991, 11: 3877–3887.

184. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O,
Burrell JR, et al. Amyotrophic lateral sclerosis. Lancet 2011, 377:
942–955.

185. Marangi G, Traynor BJ. Genetic causes of amyotrophic lateral sclerosis:
new genetic analysis methodologies entailing new opportunities and
challenges. Brain Res 2015, 1607: 75–93.

186. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley
S, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral
sclerosis. Science 2008, 319: 1668–1672.

187. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ,
Vande Velde C, Bouchard JP, et al. TARDBP mutations in individuals
with sporadic and familial amyotrophic lateral sclerosis. Nat Genet
2008, 40: 572–574.

188. Kabashi E, Lin L, Tradwell ML, Dion PA, Bercier V, Bourgoin P,
Rochefort D, et al. Gain and loss of function of ALS-related mutations
of TARDBP (TDP-43) cause motor deficits in vivo. *Hum Mol Genet* 2010, 19: 671–683.

189. Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. *Ann Neurol* 2010, 67: 739–748.

190. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 2006, 314: 130–133.

191. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. *Lancet Neurol* 2010, 9: 995–1007.

192. Chio A, Calvo A, Moglia C, Restagno G, Ossola I, Brunetti M, Montuuchi A, et al. Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 families with p.Ala382Thr TARDBP mutations. *Arch Neurol* 2010, 67: 1002–1009.

193. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, Kok F, et al. A mutation in the vesicle-transporting protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. *Am J Hum Genet* 2004, 75: 822–831.

194. Anagnostou G, Akbar MT, Paul P, Angelinetta C, Steiner TJ, de Bellerocque J. Vesicle associated membrane protein B (VAPB) is decreased in ALS spinal cord. *Neurobiol Aging* 2010, 31: 969–985.

195. Huang WJ, Chen WW, Zhang X. Multiple sclerosis: pathology, diagnosis and treatments. *Exp Ther Med* 2017, 13: 3163–3166.

196. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, et al. New susceptibility variants for multiple sclerosis. *J Hum Genet* 2009, 54: 676–680.

197. van Luijn MM, Kreft KL, Jongsm a ML, Mes SW, Wierenga-Wolf AF, van Meurs M, Melief MJ, et al. Multiple sclerosis-associated CLEC16A controls HLA class II expression via late endosome biogenesis. *Brain* 2015, 138: 1531–1547.

198. McMurray JL, Dimova J, Pisansky MT, Sun M, Beppu H, Gewirtz JC, O’Connor MB. Forebrain-specific loss of BMPRII in mice reduces anxiety and increases object exploration. *PLoS One* 2015, 10: e0139860.

199. Agata H, Murayama A, Migishima R, Kida S, Tsuchida K, Yokoyama M, Inokuchi K. Activin in the brain modulates anxiety-related behavior and adult neurogenesis. *PLoS One* 2008, 3: e1869.

200. Sutcuil I, Oktenli C, Musabak U, Borkurt A, Cansever A, Uzun O, San sosoglu SY, et al. A pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. *Clin Dev Immunol* 2007, 2007: 76396.

201. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arot V, et al. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression—no influence of celecoxib treatment. *J Affect Disord* 2011, 134: 217–225.

202. Mihailova S, Ivanova-Genova E, Lukanov T, Stoyanova V, Milanova V, Naumova E. A study of TNF-alpha, TGF-beta, IL-10, IL-6, and IFN-gamma gene polymorphisms in patients with depression. *J Neuroimmunol* 2016, 293: 123–128.

203. Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. *Int Immunopharmacol* 2006, 6: 1298–1304.

204. Globeske KT, Das S, Bonaguidi MA, Weiss C, Radulovic J, Disterhoft JF, Kessler JA. BMP signaling mediates effects of exercise on hippocampal neurogenesis and cognition in mice. *PLoS One* 2009, 4: e7506.

205. John GR, Shankar SL, Shahit-Zagardo B, Massimi A, Lee SC, Raine CS, Brosnan CF. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. *Nat Med* 2002, 8: 1115–1121.

206. Setoguchi T, Nakashima K, Takeiwa T, Yanagisawa M, Ochait W, Okabe M, Yone K, et al. Treatment of spinal cord injury by transplantation of fetal neural precursor cells engineered to express BMP inhibitor. *Exp Neurol* 2004, 189: 33–44.

207. Haller DA, Compston A, Sawyer S, Lander ES, Daly MJ, De Jager PL, de Bakker PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. *N Engl J Med* 2007, 357: 851–862.

208. Hoppenbrouwers IA, Aulchenko YS, Janssens AC, Ramagopal SV, Broer L, Kayser M, Ebers GC, et al. Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. *J Hum Genet* 2009, 54: 676–680.

209. van Luijn MM, Kreft KL, Jonsga MA, Mes SW, Wierenga-Wolf AF, van Meurs M, Melief MJ, et al. Multiple sclerosis-associated CLEC16A controls HLA class II expression via late endosome biogenesis. *Brain* 2015, 138: 1531–1547.

210. McBrayer ZL, Dimova J, Pisansky MT, Sun M, Beppu H, Gewirtz JC, O’Connor MB. Forebrain-specific loss of BMPRII in mice reduces anxiety and increases object exploration. *PLoS One* 2015, 10: e0139860.

211. Ageta H, Murayama A, Migishima R, Kida S, Tsuchida K, Yokoyama M, Inokuchi K. Activin in the brain modulates anxiety-related behavior and adult neurogenesis. *PLoS One* 2008, 3: e1869.

212. Sutcuil I, Oktenli C, Musabak U, Borkurt A, Cansever A, Uzun O, San sosoglu SY, et al. A pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. *Clin Dev Immunol* 2007, 2007: 76396.

213. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arot V, et al. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression—no influence of celecoxib treatment. *J Affect Disord* 2011, 134: 217–225.

214. Mihailova S, Ivanova-Genova E, Lukanov T, Stoyanova V, Milanova V, Naumova E. A study of TNF-alpha, TGF-beta, IL-10, IL-6, and IFN-gamma gene polymorphisms in patients with depression. *J Neuroimmunol* 2016, 293: 123–128.

215. Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. *Int Immunopharmacol* 2006, 6: 1298–1304.

216. Globeske KT, Das S, Bonaguidi MA, Weiss C, Radulovic J, Disterhoft JF, Kessler JA. BMP signaling mediates effects of exercise on hippocampal neurogenesis and cognition in mice. *PLoS One* 2009, 4: e7506.

217. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. *Nat Genet* 2005, 37: 806–808.

218. West RJ, Lu Y, Marie B, Gao FB, Sweeney ST, RahB, POSH, and TAK1 regulate synaptic growth in a Drosophila model of frontotemporal dementia. *J Cell Biol* 2015, 208: 931–947.